Algert Global LLC acquired a new stake in shares of Enzo Biochem, Inc. (NYSE:ENZ) during the fourth quarter, HoldingsChannel reports. The fund acquired 44,363 shares of the medical research company’s stock, valued at approximately $362,000.

Several other hedge funds and other institutional investors also recently modified their holdings of the company. Schwab Charles Investment Management Inc. boosted its stake in Enzo Biochem by 19.2% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 125,281 shares of the medical research company’s stock valued at $1,384,000 after purchasing an additional 20,200 shares during the period. Bank of New York Mellon Corp boosted its stake in Enzo Biochem by 7.1% during the 2nd quarter. Bank of New York Mellon Corp now owns 221,166 shares of the medical research company’s stock valued at $2,442,000 after purchasing an additional 14,719 shares during the period. Legal & General Group Plc boosted its stake in Enzo Biochem by 10.6% during the 2nd quarter. Legal & General Group Plc now owns 10,663 shares of the medical research company’s stock valued at $119,000 after purchasing an additional 1,022 shares during the period. Alliancebernstein L.P. bought a new stake in Enzo Biochem during the 2nd quarter valued at approximately $1,271,000. Finally, Teachers Advisors LLC boosted its stake in Enzo Biochem by 6.8% during the 2nd quarter. Teachers Advisors LLC now owns 150,354 shares of the medical research company’s stock valued at $1,660,000 after purchasing an additional 9,609 shares during the period. 65.32% of the stock is currently owned by institutional investors and hedge funds.

Shares of Enzo Biochem, Inc. (NYSE ENZ) opened at $6.98 on Tuesday. Enzo Biochem, Inc. has a 52 week low of $6.36 and a 52 week high of $12.04. The firm has a market capitalization of $337.87, a P/E ratio of -180.00 and a beta of 0.70.

Enzo Biochem (NYSE:ENZ) last announced its quarterly earnings data on Thursday, December 7th. The medical research company reported ($0.01) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.01). Enzo Biochem had a negative return on equity of 1.89% and a negative net margin of 1.53%. The company had revenue of $27.68 million during the quarter, compared to the consensus estimate of $27.51 million. equities analysts forecast that Enzo Biochem, Inc. will post -0.02 earnings per share for the current year.

In other Enzo Biochem news, CEO Elazar Rabbani sold 14,000 shares of the firm’s stock in a transaction that occurred on Wednesday, January 17th. The stock was sold at an average price of $7.75, for a total value of $108,500.00. Following the completion of the sale, the chief executive officer now owns 1,867,202 shares in the company, valued at approximately $14,470,815.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Barry W. Weiner sold 11,000 shares of the firm’s stock in a transaction that occurred on Wednesday, January 17th. The stock was sold at an average price of $7.75, for a total value of $85,250.00. Following the completion of the sale, the chief financial officer now owns 1,313,111 shares of the company’s stock, valued at approximately $10,176,610.25. The disclosure for this sale can be found here. 8.90% of the stock is currently owned by company insiders.

TRADEMARK VIOLATION WARNING: “Algert Global LLC Invests $362,000 in Enzo Biochem, Inc. (ENZ)” was first published by Watch List News and is owned by of Watch List News. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international trademark and copyright legislation. The legal version of this article can be read at https://www.watchlistnews.com/algert-global-llc-invests-362000-in-enzo-biochem-inc-enz/1847311.html.

Enzo Biochem Profile

Enzo Biochem, Inc is a bioscience company focusing on delivering and applying technology capabilities to produce products and services. The Company’s segments include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies.

Want to see what other hedge funds are holding ENZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enzo Biochem, Inc. (NYSE:ENZ).

Institutional Ownership by Quarter for Enzo Biochem (NYSE:ENZ)

Receive News & Ratings for Enzo Biochem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem and related companies with MarketBeat.com's FREE daily email newsletter.